منابع مشابه
Inhibition of breast cancer metastasis by co-transfection of miR-31/193b-mimics
Objective(s): Various studies have been conducted to reduce the metastatic behavior of cancerous cells. In this regard, ectopic expression of anti-metastatic microRNAs by miR-mimic and miR-restoration-based therapies could bring new insights to the field. In the present study, the consequences of co-transfecting breast cancer cell lines with miR-193b and miR-31 were investigated via invasion an...
متن کاملArterial Stiffness and Arterial Aging
The process of population ageing that is occurring in developed societies represents a major challenge for the health system. Cardiovascular diseases (CVD) are the most common cause of morbidity and mortality in the world, representing half of the deaths in people over 65 years old. Among the CVD, systemic arterial hypertension is related to more than half of those outcomes [1]. The non-modifia...
متن کاملSegmental arterial mediolysis mimics systemic vasculitis.
Segmental arterial mediolysis (SAM) is a rare, nonarteriosclerotic, noninflammatory vascular disease and mostly affects medium-to-large sized abdominal arteries as well as presents with hemorrhages in the abdominal cavity. We report the case of a patient with SAM of the celiac, right renal, jejunal branch of the superior mesenteric, left gastric, and splenic arteries who was diagnosed by exclud...
متن کاملAging and arterial stiffness.
Arterial walls stiffen with age. The most consistent and well-reported changes are luminal enlargement with wall thickening and a reduction of elastic properties at the level of large elastic arteries. Longstanding arterial pulsation in the central artery causes elastin fiber fatigue and fracture. Increased vascular calcification and endothelial dysfunction are also characteristic of arterial a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The FASEB Journal
سال: 2015
ISSN: 0892-6638,1530-6860
DOI: 10.1096/fasebj.29.1_supplement.1047.3